Crinetics Pharmaceuticals, Inc. · NASDAQ:CRNX

Crinetics Pharmaceuticals — ENDO 2025

13 slides from Crinetics Pharmaceuticals's conference presentation, July 2025

  1. Slide 1: Once-daily oral atumelnant in adults with classical CAH: interim Phase 2 results

    ONCE-DAILY ORAL ATUMELNANT (CRN04894) INDUCES RAPID, SUBSTANTIAL, AND SUSTAINED REDUCTIONS OF ANDROSTENEDIONE AND 17-HYDROXYPROGESTERONE IN ADULTS WITH CLASSICAL CONGENITAL ADRENAL HYPERPLASIA: INTERIM RESULTS FROM A 12-WEEK, PHASE 2, OPEN-LABEL STUDY Presenter: Umasuthan Srirangalingam, MD, PhD, on

  2. Slide 2: Authors

    Authors Umasuthan Srirangalingam, MD, PhD1; Dario Bruera, MD2; Alejandro Ayala, MD3; Yang Wu, PhD3; Eduardo De la Torre Ames, MD3; Alan Krasner, MD3; Mônica R. Gadelha, MD, PhD4; Nicole Reisch, MD5; Flavia Amanda Costa-Barbosa, MD, PhD6; Vania dos Santos Nunes-Nogueira, MD7; Richard J. Auchus, MD, P

  3. Slide 3: Author disclosures

    Author disclosures This study was sponsored by Crinetics Pharmaceuticals, Inc. U Srirangalingam received consulting fees from Crinetics Pharmaceuticals, Diurnal Ltd, and H Lundbeck A/S. D Bruera has nothing to disclose. A Ayala, Y Wu, EDl Torre Ames, and A Krasner are employees of Crinetics Pharmace

  4. Slide 4: Background

    Background • Atumelnant (CRN04894) is a first-in-class, once-daily, oral, nonpeptide, MC2R antagonist1 • Selectively and specifically inhibits ACTH- mediated adrenal steroidogenesis2 • Being developed for the treatment of CAH and ACTH-dependent Cushing’s syndrome Objective • To present results from

  5. Slide 5: Methods

    Methods Key Eligibility Criteria Treatment Arms: • Male or female participants age ≥18 to • Completed cohorts, each 12 weeks (N=28) 75 years (≥16 years in USA) • Atumelnant, administered once daily, at night • Classic CAH (21-hydroxylase deficiency) 40 mg (n=11) • On ≥15 mg hydrocortisone equivalent

  6. Slide 6: Demographics and Baseline Characteristics

    Demographics and Baseline Characteristics Atumelnant Atumelnant Atumelnant All participants Parameter 40 mg (n=11) 80 mg (n=11) 120 mg (n=6) (N=28) Age, years, mean (range) 28.0 (20-45) 33.0 (22-42) 34.0 (22-47) 31.3 (20-47) Female, n (%) 4 (36.4) 8 (72.7) 3 (50.0) 15 (53.6) Baseline biomarker level

  7. Slide 7: Rapid, Substantial, and Sustained Reduction in Pre-GC Morning Serum A4 With Atumelnant

    Rapid, Substantial, and Sustained Reduction in Pre-GC Morning Serum A4 With Atumelnant Reduction in A4 From Baseline to Week 12 Reduction in A4 From Baseline With Atumelnant Week 0 Baseline 2 6 12 0 Atumelnant 40 mg Mean (SE) Percent Change From Baseline in Morning Serum A4 Mean (SE) Change From Bas

  8. Slide 8: Rapid, Substantial, and Sustained Reduction in Pre-GC Morning Serum 17-OHP With Atumelnant

    Rapid, Substantial, and Sustained Reduction in Pre-GC Morning Serum 17-OHP With Atumelnant Reduction in 17-OHP From Baseline to Week 12 Reduction in 17-OHP From Baseline With Atumelnant Week 0 Baseline 2 6 12 0 Baseline In Morning Serum 17-OHP Mean (SE) Percent Change From Atumelnant 40 mg in Mornin

  9. Slide 9: Pre-GC Serum A4:Testosterone Was Reduced in Male Participants

    Pre-GC Serum A4:Testosterone Was Reduced in Male Participants in All Atumelnant Dose Cohorts Reduction in A4:Testosterone From Baseline With Atumelnant Change in A4:Testosterone From Baseline to Week Week 12 for Individual Participantsa Baseline 2 6 12 0 12 Baseline in Morning Serum A4:T -1 10 Mean

  10. Slide 10: Female Participants Experienced Improvements in Reproductive Health With Atumelnant

    Female Participants Experienced Improvements in Reproductive Health With Atumelnant Reduction in Testosterone From Baseline With Atumelnant 100 Week • Regular menstruation was resumed in Morning Serum Testosterone (ng/dL) 2 6 12 Baseline Mean (SE) Change From Baseline 0 by Week 12 in 6/10 participan

  11. Slide 11: Summary of TEAEs

    Summary of TEAEs Atumelnant Atumelnant Atumelnant All participants Participants with TEAE, n (%) 40 mg (n=11) 80 mg (n=11) 120 mg (n=6) (N=28) ≥1 TEAE 8 (72.7) 8 (72.7) 5 (83.3) 21 (75.0) • No severe or serious TEAEs occurring in ≥2 total participants TEAEs were observed Headache 2 (18.2) 4 (36.4) 2

  12. Slide 12: Conclusions

    Conclusions • Once-daily, oral atumelnant showed profound, rapid, and sustained suppression of A4 and 17-OHP in participants with CAH, with clinical activity observed across all doses • Reductions of 80% and 65% in A4 and 17-OHP, respectively, were achieved in the 120-mg cohort • Atumelnant resulted

  13. Slide 13: Thank You

    THANK YOU ENDO 2025 ● July 12-15, 2025 ● San Francisco, California, USA CRINETICS PHARMACEUTICALS | 13

Crinetics Pharmaceuticals — ENDO 2025 on 6ix